Proinflammatory circulating markers: new players for evaluating asymptomatic acute cardiovascular toxicity in breast cancer treatment

References

• Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P, Cohen Solal A, Zamorano J-L, Jerusalem G, Moonen M, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J. 2019; 40(22):1756–63.
   PubMed Web of Science ®Google Scholar
• Martel S, Maurer C, Lambertini M, Pondé N, De Azambuja E. Breast cancer treatment-induced cardiotoxicity. Expert Opin Drug Saf. 2017;16(9):1021–38.
   PubMed Web of Science ®Google Scholar
• Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2. J Am Coll Cardiol. 2017;70(20):2552–65.
   PubMedGoogle Scholar
• Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc. 2019; 25:100420
   PubMed Web of Science ®Google Scholar
• Carver JR, Szalda D, Ky B. Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance. Semin Oncol. 2013;40(2):229–38.
   PubMed Web of Science ®Google Scholar
• Ades F, Zardavas D, Pinto AC, Criscitiello C, Aftimos P, De Azambuja E. Cardiotoxicity of systemic agents used in breast cancer. Breast. 2014; 23(4):317–28.
   PubMed Web of Science ®Google Scholar
• Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30–e66.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–90.
   PubMed Web of Science ®Google Scholar
• Mavrogeni SI, Sfendouraki E, Markousis-Mavrogenis G, Rigopoulos A, Noutsias M, Kolovou G, Angeli C, Tousoulis D. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors. Heart Fail Rev. 2019;24(6):977–87.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457–67.
   PubMed Web of Science ®Google Scholar
• Goldvaser H, Barnes TA, Seruga B, Cescon DW, Ocaña A, Ribnikar D, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018; 110(1):10.1093.
   Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Untch M, Smith I, Gianni L, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–205.
   PubMed Web of Science ®Google Scholar
• Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B, Moslehi J, Mulrooney DA, Nathan PC, Ryan TD, et al. al. Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention. J Clin Oncol. 2018;36(21):2135–44.
   PubMed Web of Science ®Google Scholar
• Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu JV, Fung K, Anderson GM. Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study. Eur Heart J. 2019; 40(48):3913–20.
   PubMed Web of Science ®Google Scholar
• Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand J-B, Ewer M, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2017; 35(8):893–911.
   PubMed Web of Science ®Google Scholar
• Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019; 280:163–75.
   PubMed Web of Science ®Google Scholar
• Cardinale DM, Barac A, Torbicki A, Khandheria BK, Lenihan D, Minotti G. Cardio-oncological management of patients. Semin Oncol. 2019; 46(6):408–13.
   PubMed Web of Science ®Google Scholar
• Jain D, Ahmad T, Cairo M, Aronow W. Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment [retracted in. Ann Transl Med. 2017;5(17):348.
   PubMed Web of Science ®Google Scholar
• Danese E, Montagnana M. An historical approach to the diagnostic biomarkers of acute coronary syndrome. Ann Transl Med. 2016;4(10):194.
   PubMed Web of Science ®Google Scholar
• Kragten JA, Hermens WT, van Dieijen-Visser MP. Cardiac troponin T release into plasma after acute myocardial infarction: only fractional recovery compared with enzymes. Ann Clin Biochem. 1996;33(4):314–23.
   PubMedGoogle Scholar
• Nordgren KKS, Hampton M, Wallace KB. Editor's highlight: the altered DNA methylome of chronic doxorubicin exposure in sprague dawley rats. Toxicol Sci. 2017;159(2):470–9.
   PubMed Web of Science ®Google Scholar
• Leong SL, Chaiyakunapruk N, Lee SW. Candidate gene association studies of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis. Sci Rep. 2017;7(1):39.
   PubMedGoogle Scholar
• Panis C, Binato R, Correa S, Victorino VJ, Dias-Alves V, Herrera ACSA, Cecchini R, Simão ANC, Barbosa DS, Pizzatti L, et al. Short infusion of paclitaxel imbalances plasmatic lipid metabolism and correlates with cardiac markers of acute damage in patients with breast cancer. Cancer Chemother Pharmacol. 2017;80(3):469–78.
   PubMed Web of Science ®Google Scholar
• Panis C, Pizzatti L, Bufalo AC, Herrera AC, Victorino VJ, Cecchini R, Abdelhay E. Early downregulation of acute phase proteins after doxorubicin exposition in patients with breast cancer. Tumour Biol. 2016;37(3):3775–83.
   PubMedGoogle Scholar
• Ürun Y, Utkan G, Yalcin B, Akbulut H, Onur H, Oztuna DG, Şenler FC, Demirkazık A, İçli F. The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer. Exp Oncol. 2015; 37(1):53–7.
   PubMedGoogle Scholar
• Skovgaard D, Hasbak P, Kjaer A. BNP predicts chemotherapy-related cardiotoxicity and death: Comparison with gated equilibrium radionuclide ventriculography. PLoS One. 2014; 9(5):e96736.
   PubMed Web of Science ®Google Scholar
• Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, et al. al. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Res Treat. 2018;168(3):631–8.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910–6.
   PubMed Web of Science ®Google Scholar
• Finkelman BS, Putt M, Wang T, Wang L, Narayan H, Domchek S, DeMichele A, Fox K, Matro J, Shah P, et al. Arginine-nitric oxide metabolites and cardiac dysfunction in patients with breast cancer. J Am Coll Cardiol. 2017;70(2):152–62.
   PubMed Web of Science ®Google Scholar
• Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. JACC Cardiovasc Imaging. 2018;11(8):1084–93.
   PubMed Web of Science ®Google Scholar
• Levis BE, Binkley PF, Shapiro CL. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms? Lancet Oncol. 2017;18(8):e445–e456.
   PubMed Web of Science ®Google Scholar
• Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, et al. Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)). J Clin Oncol. 2017;35(23):2647–55.
   PubMed Web of Science ®Google Scholar
• Carvalho RA, Sousa RPB, Cadete VJJ, Lopaschuk GD, Palmeira CMM, Bjork JA, Wallace KB. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology. 2010; 270(2-3):92–8.
   PubMed Web of Science ®Google Scholar
• Tromp J, Khan MAF, Klip IT, Meyer S, de Boer RA, Jaarsma T, et al. Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J Am Heart Assoc. 2017;6(4):e003989.
   PubMed Web of Science ®Google Scholar
• Ky B, Putt M, Sawaya H, French B, Januzzi JL, Sebag IA, Plana JC, Cohen V, Banchs J, Carver JR, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63(8):809–16.
   PubMed Web of Science ®Google Scholar
• Scuric Z, Carroll JE, Bower JE, Ramos-Perlberg S, Petersen L, Esquivel S, Hogan M, Chapman AM, Irwin MR, Breen EC, et al. Biomarkers of aging associated with past treatments in breast cancer survivors. NPJ Breast Cancer. 2017;3(1):50.
   PubMedGoogle Scholar
• Tromp J, Boerman LM, Sama IE, Maass SWMC, Maduro JH, Hummel YM, Berger MY, Bock GH, Gietema JA, Berendsen AJ, et al. Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls. Eur J Heart Fail. 2020;22(7):1239–46.
   PubMed Web of Science ®Google Scholar
• Mythili S, Malathi N. Diagnostic markers of acute myocardial infarction. Biomed Rep. 2015; 3(6):743–8.
   PubMed Web of Science ®Google Scholar
• Dirican A, Levent F, Alacacioglu A, Kucukzeybek Y, Varol U, Kocabas U, Şenöz O, Emren SV, Demir L, Coban E, et al. Acute cardiotoxic effects of adjuvant trastuzumab treatment and its relation to oxidative stress. Angiology. 2014; 65(10):944–9.
   PubMedGoogle Scholar
• Kabel AM, Elkhoely AA. Targeting proinflammatory cytokines, oxidative stress, TGF-β1 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity. Biomed Pharmacother. 2017;93:17–26.
   PubMed Web of Science ®Google Scholar
• Yu AF, Yadav NU, Lung BY, Eaton AA, Thaler HT, Hudis CA, Dang CT, Steingart RM. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat. 2015;149(2):489–95.
   PubMed Web of Science ®Google Scholar
• Rochette L, Guenancia C, Gudjoncik A, Hachet O, Zeller M, Cottin Y, Vergely C. Anthracyclines/trastuzumab: New aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci. 2015;36(6):326–48.
   PubMed Web of Science ®Google Scholar
• Saad SY, Najjar TAO, Alashari M. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: Effect of sequence and timing of administration. J Biochem Mol Toxicol. 2004;18(2):78–86.
   PubMed Web of Science ®Google Scholar
• Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011; 17(10):3490–9.
   PubMed Web of Science ®Google Scholar
• Torzewski J, Hombach V, Nienhaus GU. C-reactive protein and atherosclerosis: an update. Vasc Dis Prev. 2008;5(1):178–82.
   Google Scholar
• Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, Pepys MB. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190(12):1733–9.
   PubMed Web of Science ®Google Scholar
• Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, Picard MH, Carver JR, Halpern EF, Kuter I, et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem. 2015; 61(9):1164–72.
   PubMed Web of Science ®Google Scholar
• Freedman RJ, Aziz N, Albanes D, Hartman T, Danforth D, Hill S, Sebring N, Reynolds JC, Yanovski JA. Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J Clin Endocrinol Metab. 2004;89(5):2248–53.
   PubMed Web of Science ®Google Scholar
• Bell KE, Di Sebastiano KM, Vance V, Hanning R, Mitchell A, Quadrilatero J, Russell C, Dubin JA, Bahl M, Califaretti N, et al. A comprehensive metabolic evaluation reveals impaired glucose metabolism and dyslipidemia in breast cancer patients early in the disease trajectory. Clin Nutr. 2014;33(3):550–7.
   PubMed Web of Science ®Google Scholar
• Arpino G, De Angelis C, Buono G, Colao A, Giuliano M, Malgieri S, Cicala S, De Laurentiis M, Accurso A, Crispo A, et al. Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy. Breast Cancer Res Treat. 2015;154(1):127–32.
   PubMed Web of Science ®Google Scholar
• Schatzkin A, Hoover RN, Taylor PR, Ziegler RG, Carter CL, Albanes D, Larson DB, Licitra LM. Site-specific analysis of total serum cholesterol and incident cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Cancer Res. 1988;48(2):452–8.
   PubMed Web of Science ®Google Scholar
• Forones NM, Falcao JB, Mattos D, Barone B. Cholesterolemia in colorectal cancer. Hepatogastroenterology. 1998;45(23):1531–4.
   PubMedGoogle Scholar
• Laisupasin P, Thompat W, Sukarayodhin S, Sornprom A, Sudjaroen Y. Comparison of serum lipid profiles between normal controls and breast cancer patients. J Lab Physicians. 2013;5(01):38–41.
   PubMedGoogle Scholar
• Bani IA, Williams CM, Boulter PS, Dickerson JWT. Plasma lipids and prolactin in patients with breast cancer. Br J Cancer. 1986;54(3):439–46.
   PubMed Web of Science ®Google Scholar
• Sharma M, Tuaine J, McLaren B, Waters DL, Black K, Jones LM, McCormick SPA. Chemotherapy agents alter plasma lipids in breast cancer patients and show differential effects on lipid metabolism genes in liver cells. PLoS One. 2016;11(1):e0148049.
   PubMed Web of Science ®Google Scholar
• Alexopoulos CG, Pournaras S, Vaslamatzis M, Avgerinos A, Raptis S. Changes in serum lipids and lipoproteins in cancer patients during chemotherapy. Cancer Chemother Pharmacol. 1992;30(5):412–6.
   PubMed Web of Science ®Google Scholar
• Leger KJ, Baker KS, Cushing-Haugen KL, Flowers MED, Leisenring WM, Martin PJ, Mendoza JA, Reding KW, Syrjala KL, Lee SJ, et al. Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer. 2018;124(7):1507–15.
   PubMed Web of Science ®Google Scholar
• Scott JM, Iyengar NM, Nilsen TS, Michalski M, Thomas SM, Herndon J, Sasso J, Yu A, Chandarlapaty S, Dang CT, et al. Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: a randomized controlled trial. Cancer. 2018;124(12):2552–60.
   PubMed Web of Science ®Google Scholar
• van der Meer P, Gietema JA, Suter TM, van Veldhuisen DJ. Cardiotoxicity of breast cancer treatment: no easy solution for an important long-term problem. Eur Heart J. 2016;37(21):1681–3.
   PubMed Web of Science ®Google Scholar
• Fan CD, Sun JY, Fu XT, Hou YJ, Li Y, Yang MF, Fu XY, Sun BL. Astaxanthin attenuates homocysteine-induced cardiotoxicity in vitro and in vivo by inhibiting mitochondrial dysfunction and oxidative damage. Front Physiol. 2017; 8:1041.
   PubMed Web of Science ®Google Scholar
• Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12(9):547–58.
   PubMed Web of Science ®Google Scholar
• Vannucchi H, Melo SS. [Hyperhomocysteinemia and cardiometabolic risk]. Arq Bras Endocrinol Metabol. 2009;53(5):540–9.
   PubMedGoogle Scholar
• Almashhadany A, Shackebaei D, Van Der Touw T, Jones GL, Suleiman MS, King N. Homocysteine exposure impairs myocardial resistance to ischaemia reperfusion and oxidative stress. Cell Physiol Biochem. 2015;37(6):2265–74.
   PubMedGoogle Scholar
• Feng X, Xu Y. Hyperhomocysteinemia as a metabolic risk factor for glucose intolerance among high-risk groups of Chinese adults. Med Sci Monit. 2017;23 (23):2775–81.
   PubMedGoogle Scholar
• Markišić M, Pavlović AM, Pavlović DM. The impact of homocysteine, vitamin B12, and vitamin D levels on functional outcome after first-ever ischaemic stroke. Biomed Res Int. 2017;2017:1–6.
   Web of Science ®Google Scholar
• Corna G, Santambrogio P, Minotti G, Cairo G. Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J Biol Chem. 2004;279(14):13738–45.
   PubMed Web of Science ®Google Scholar
• Minotti G, Recalcati S, Menna P, Salvatorelli E, Corna G, Cairo G. Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol. 2004;378:340–61.
   PubMed Web of Science ®Google Scholar
• Bower JE, Ganz PA, Irwin MR, Kwan L, Breen EC, Cole SW. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? J Clin Oncol. 2011;29(26):3517–22.
   PubMed Web of Science ®Google Scholar
• Panis C, Pizzatti L, Herrera AC, Cecchini R, Abdelhay E. Putative circulating markers of the early and advanced stages of breast cancer identified by high-resolution label-free proteomics. Cancer Lett. 2013;330(1):57–66.
   PubMed Web of Science ®Google Scholar
• Han Y, Mao F, Wu Y, Fu X, Zhu X, Zhou S, Zhang W, Sun Q, Zhao Y. Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. Int J Biol Markers. 2011;26(4):209–15.
   PubMed Web of Science ®Google Scholar
• Suleiman NN, Nascimento N, Botelho JMS, Coelho RC. Overview of female breast cancer in northern Tocantins - Brazil. Rev Col Bras Cir. 2017;44(4):316–22.
   PubMedGoogle Scholar
• Anber ZNH, Saleh BOM, Al-Rawi SA. The cardiotoxicity effect of different chemotherapeutic regimens in Iraqi patients with breast cancer: a follow up study. Heliyon. 2019;5(8):e02194.
   PubMed Web of Science ®Google Scholar
• Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, Munster PN. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol. 2019;73(22):2859–68.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z. Immunogenic cell death in cancer therapy: Present and emerging inducers. J Cell Mol Med. 2019; 23(8):4854–65.
   PubMed Web of Science ®Google Scholar
• Mohan N, Shen Y, Endo Y, ElZarrad MK, Wu WJ. Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. Mol Cancer Ther. 2016; 15(6):1321–31.
   PubMed Web of Science ®Google Scholar
• Alanazi AM, Fadda L, Alhusaini A, Ahmad R, Hasan IH, Mahmoud AM. Liposomal resveratrol and/or carvedilol attenuate doxorubicin-induced cardiotoxicity by modulating inflammation, oxidative stress and S100A1 in rats. Antioxidants (Basel). 2020;9(2):159.
   Google Scholar
• Mobaraki M, Faraji A, Zare M, Dolati P, Ataei M, Dehghan Manshadi HR. Molecular mechanisms of cardiotoxicity: a review on the major side-effects of doxorubicin. Indian J Pharm Sci. 2017;79(3):335–44.
   Web of Science ®Google Scholar